

Last edit: June 5, 2026

Wednesday, July 15**Continental Breakfast****7:15 AM****8:15 AM****Retina Surgery Around the Globe (No CME, livestream, or recording)**

Team 1 Moderators: RV Paul Chan, MD, MSc, MBA and Mrinali Gupta, MD, FASRS Presenters: Gustavo Huning, MD, MBA, FASRS; Ajay Kuriyan, MD, MS; Ahmed Mansour, MBBCH, MSC, MD, PhD; Ayumi Ouchi, MD, MD, PhD; Cynthia Qian, MD; Sara Touhami, MD, PhD, FEBO, HDR

8:00 AM**11:00 AM**

Team 2 Moderators: Rajeev Muni, MD, MSc, FRCS(C), FASRS and Nimesh Patel, MD, FASRS Presenters: Kunihiko Akiyama, MD, PhD; Thibault Chapron, MD, PhD; Luis Escaf, MD; Natasha Ferreira Santos da Cruz, MD; Jessica Xiong, BMed/MD, Mmed

Team 3 Moderators: Jorge Fortun, MD and Aleksandra Rachitskaya, MD, FASRS Presenters: Fares Antaki, MDCM, FRCSC; Andres Aqueveque, MD, FEBO, PhD; Bruna Gil Ferriera, MD; Yassine Malek, MD; Joaquin Sosa, MD; Marcelo Ventura, MD

Circus of Complications (No CME, livestream, or recording)

Moderators: Mohsin Ali, MD; Brian Do, MD, FASRS; Lisa Olmos de Koo, MD, MBA; Priya Vakharia, MD, FASRS

11:00 AM**12:15 PM**

Presenters: Edward Korot, MD; Gregory Lee, MD; Tamara Lenis, MD, PhD; Matthew Trese, DO, MA; Malek Yassine, MD; Sarwar Zahid, MD, FASRS

General Lunch + International Lunch; Exhibits Open

12:15 PM**1:30 PM****Medical Case Conference**

Moderators: Ines Lains, MD, PhD; Anat Loewenstein, MD

1:30 PM**3:00 PM**

| | | | |
|---|---|---------|---------|
| | <p><u>Presenters:</u> Mohamed Al Bahiti, MBBS, FRCSC; Parnian Arjmand, MD, MSc, FRCSC, DABO; Poornachandra B, MS, FVRS; Kevin Blinder, MD, FASRS; Victor Chen, MD; Talisa de Carlo Forest, MD; Hector Ibanez, MD, FACS, FASRS, FABO, FAAO; Matias Igllicki, MD; Ravi Keshavamurthy, MBBS, MD; Ricardo Leal Rodriguez, MD; Sun Young (Sunny) Lee, MD, PhD, FASRS, FARVO; Yasha Modi, MD; Nader Moinfar, MD, MPH, FACS, FASRS; Samir Patel, MD; Sriharanathan Poopalaratnam, MD, FRCSC; Emil Anthony Say, MD; Kotaro Tsuboi, MD; Eduardo Uchiyama, MD, FACS</p> | | |
| Break | | 3:00 PM | 3:40 PM |
| Surgical Case Conference | <p><u>Moderators:</u> Carl Awh, MD, FASRS; Caroline Awh, MD</p> | 3:40 PM | 5:10 PM |
| | <p><u>Presenters:</u> Luis Acaba-Berrocal, MD; Sulaiman Al Sulaiman, MD; Alay Banker, MD; Mauricio Bayram-Suverza, MD; Yodpong Chantarasorn, MD; Jordan Deaner, MD; Charles DeBoer, MD, PhD; Masaki Fukushima, MD, PhD; Raymond Iezzi, MD, MS; Srinivas Joshi, MD, FASRS; Boonkit Purt, MD, FACS; Padmaja Rani, M.S, FICO, FRCSC; Mary-Grace Reeves, MD, MBA; Geovanni Rios, PhD, MD; Pukhraj Rishi, MBBS, MS, DO, FRCSC, FRCSEd, FASRS, FACS; Ahmed Sallam, MD PhD FRCOphth; Homayoun Tabandeh, MD, FASRS; Christina Weng, MD, MBA, FASRS</p> | | |
| Opening Reception: Grand Quai Pavilion | | 6:30 PM | |
| Thursday, July 16 | | | |
| Experience Center (Fellows & Residents) | | 6:30 AM | 7:30 AM |
| Continental Breakfast | | 7:15 AM | 8:15 AM |
| Opening Comments | | 8:00 AM | 8:05 AM |
| Welcome to Montreal | | 8:05 AM | 8:10 AM |
| AMD - Neovascular Panel. <i>Beyond Anti-VEGF: Emerging Durable Therapies in Neovascular AMD</i> | | 8:10 AM | 8:45 AM |

| | | | |
|--|---|----------------|----------------|
| One-year, First-in-Human, Safety and Efficacy Data for Subretinal NG101 - a Novel Low-dose AAV Gene Therapy for Wet AMD: A Phase 1/2a Clinical Trial | Peter Kertes, MD, FRCS(C) | | |
| Ixoberogene soroparvovec (Ixo-vec) intravitreal gene therapy for neovascular age-related macular degeneration (nAMD): LUNA trial 2-year results | Shawn Kavoussi, MD | | |
| Ixoberogene soroparvovec intravitreal gene therapy for neovascular age-related macular degeneration: Long-term results from the OPTIC trial | Szilard Kiss, MD, FASRS | | |
| Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-Related Macular Degeneration: Efficacy and Safety Results from the Phase 3 SOL-1 Trial | Dilsher Dhoot, MD | | |
| Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Neovascular Age-Related Macular Degeneration | David Eichenbaum, MD, FASRS | | |
| Efficacy and safety of aflibercept 8 mg in previously treated patients with nAMD or DME: 24-week results from the phase 3b ELARA trial | Eric Schneider, MD | | |
| Discussion | | | |
| <i>Transition</i> | | 8:45 AM | 8:47 AM |
| Real-World Symposium 1. Real-World nAMD: Utilization, Outcomes, and Long-Term Anti-VEGF Data | | 8:47 AM | 9:11 AM |
| Utilization and Trends in Anti-Angiogenic and Anti-Complement Therapeutics from 2023-2025 | Anton Kolomeyer, MD, PhD | 8:47 AM | 8:50 AM |
| Real-World Anti-VEGF Treatment Utilization and Vision Outcomes in Neovascular Age-Related Macular Degeneration: Analysis of the Vestrum Database | Andrew Moshfeghi, MD, MBA, FASRS | 8:50 AM | 8:53 AM |
| Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: First Time 4.5 Year Results of the TRUCKEE Study | Carl Danzig, MD | 8:53 AM | 8:56 AM |
| Long-Term Effectiveness and Safety of Faricimab in Eyes With nAMD: 2-Year Results From the UK FARWIDE Study | Ian Pearce, MB ChB BSc FRCOPHTH | 8:56 AM | 8:59 AM |
| Discussion | | 8:59 AM | 9:11 AM |
| <i>Transition</i> | | 9:11 AM | 9:13 AM |

| | | | |
|--|--|-----------------|-----------------|
| Surgical Techniques and Maneuvers Panel. <i>Mastering Scleral Fixation: Techniques, Pearls, and Pitfalls</i> | | 9:13 AM | 9:43 AM |
| A NOVEL MODIFIED FLAPLESS SURGICAL TECHNIQUE FOR SUTURELESS SCLERAL FIXATION OF FIL SSF INTRAOCULAR LENS: A PROSPECTIVE STUDY | Danilo Iannetta, MD, PhD | | |
| Closed-Globe Internal Refixation of Dislocated PMMA Scleral-Fixated IOLs Using a Modified Double-Flanged Polypropylene Technique: A prospective interventional study | Srinivas Joshi, MD, FASRS | | |
| Sutureless Flanged Versus Gore-Tex for Secondary IOL implantation: A Comparative Analysis of Surgical Philosophy, Biomechanics, and Clinical Outcomes | Matias Iglicki, MD | | |
| Lens Tilt and Dislocation After Modified Yamane Fixation: Association With Prophylactic Laser to the Optic-Haptic Junction | Harris Sultan, MS, MD | | |
| Platform Matters? - Comparative Effectiveness of Five Vitrectomy Systems in 1,082 Primary Vitreoretinal Surgeries | Obuli Nandhakumar, MD, MRCS, AMPH | | |
| Discussion | | | |
| Break | | 9:43 AM | 10:23 AM |
| AMD - Neovascular Symposium 1. <i>Rethinking nAMD Care: Home OCT, Treatment Burden, and Real-World Barriers</i> | | 10:23 AM | 10:47 AM |
| Longitudinal Performance of a Trend Analysis Algorithm for Home OCT Monitoring in Neovascular Age-related Macular Degeneration (NVAMD) | Anat Loewenstein, MD | 10:23 AM | 10:26 AM |
| Macular Ganglion Cell Layer Stability After Repeated Anti-VEGF Therapy in Eyes With and Without Primary Open-Angle Glaucoma | Marco Rovati, MD | 10:26 AM | 10:29 AM |
| Economic Evaluation of Home OCT: Determinants of Cost-Sparing Potential, Patient Selection, and Clinical Burden | Sean Berkowitz, MD, MBA | 10:29 AM | 10:32 AM |
| Impact of Treatment Delays Due to Prior Authorization on Short-term Visual Acuity in Neovascular Age-Related Macular Degeneration | Mingyi Huang, MD | 10:32 AM | 10:35 AM |
| Discussion | | 10:35 AM | 10:47 AM |
| Transition | | 10:47 AM | 10:49 AM |

| | | | |
|--|--|-----------------|-----------------|
| Imaging - Digital - Angiography Symposium. <i>Innovations in Retinal Angiography and Functional Imaging</i> | | 10:49 AM | 11:08 AM |
| Optoretinography (ORG) for Macular Dysfunction | Kareem Moussa, MD | 10:49 AM | 10:52 AM |
| Diagnostic accuracy and sensitivity of ultra-widefield steering-based imaging to detect peripheral retinal breaks | Kevin Blinder, MD, FASRS | 10:52 AM | 10:55 AM |
| Synergistic Visions - OCT Angiography and Dynamic Adaptive Optics Angiography for Clinical Assessment of Retinal Microvasculopathy | Richard Rosen, MD, DSc(Hon), FACS, FASRS, FARVO | 10:55 AM | 10:58 AM |
| Discussion | | 10:58 AM | 11:08 AM |
| <i>Transition</i> | | 11:08 AM | 11:10 AM |
| Complications of Anterior Segment Surgery Panel. <i>When Things Go Wrong: Complications and Decision-Making in Secondary IOL Surgery</i> | | 11:10 AM | 11:35 AM |
| Comparative Outcomes of Secondary Intraocular Lens Fixation Techniques: Retrospective Analysis of 935 case | Bryon McKay, MD, PhD, FRCSC, DRCPSC - Retina | | |
| Is 20/20 Vision Good Enough? Outcomes of Complete Pars Plana Vitrectomy During IOL Exchange for Lens Opacification in Patients with Preserved Visual Acuity | Ofri Vorobichik Berar, MD, MHA | | |
| Scleral-Suture Secondary Intraocular Lens Implantation Using a Modified Scleral Mesh (Hash-Tag) Technique: Case Series | Carmen Negrin-Martin, MD | | |
| Structural and Functional Outcomes and Recovery Spectrum in Intracameral Cefuroxime Ocular Toxic Syndrome (ICOTS) in Eyes with Disrupted Intraocular Barrier | Andrea Cusumano, MD | | |
| Discussion | | | |
| <i>Transition</i> | | 11:35 AM | 11:37 AM |
| Awards Ceremony | | 11:37 AM | 12:14 PM |
| Pyron Award Introduction | Geoffrey G. Emerson, MD, PhD, FASRS | 11:37 AM | 11:39 AM |
| Pyron Award: Deep Learning Algorithm to Quantify Gyrate Atrophy Lesions | Glenn Jaffe, MD | 11:39 AM | 11:44 AM |
| Founders Award Introduction | Audina Berrocal, MD, FASRS | 11:44 AM | 11:46 AM |
| Founders Award: From Illumination to Visualization: A Laser Light Source and an Illuminated Vitreous Cutter | Carl Awh, MD, FASRS | 11:46 AM | 11:51 AM |
| Young Investigator Award Introduction | J. Michael Jumper, MD, FASRS | 11:51 AM | 11:53 AM |

| | | | |
|---|--|-----------------|----------------|
| Young Investigator Award: The Retina Mosaic | Yoshihiro Yonekawa, MD, FASRS | 11:53 AM | 11:58 AM |
| Packo Award Presentation to Joel Pearlman, MD, PhD | Geoffrey G. Emerson, MD, PhD, FASRS | 11:58 AM | 12:00 PM |
| Crystle Apple Award Presentation to Herbert Culver Boldt, MD | Brian Do, MD, FASRS & Priya Vakharia, MD, FASRS | 12:00 PM | 12:02 PM |
| WinR Champion Award | | 12:02 PM | 12:04 PM |
| Tribute Giving | J. Michael Jumper, MD, FASRS | 12:04 PM | 12:06 PM |
| 2026 M. Gilbert Grand ASRS Vitreoretinal Fellowship Award | J. Michael Jumper, MD, FASRS | 12:06 PM | 12:08 PM |
| Retina Image Bank Image of the Year | Ajay Kuriyan, MD, MS & Katherine Talcott, MD | 12:08 PM | 12:09 PM |
| Retina Atlas Chapter of the Year | Ajay Kuriyan, MD, MS & Katherine Talcott, MD | 12:09 PM | 12:10 PM |
| Retina Hall of Fame Lifetime Achievement Award | John Thompson, MD | 12:10 PM | 12:12 PM |
| Transition | | 12:12 PM | 12:14 PM |
| General Lunch + ECS Lunch | | 12:14 PM | 1:29 PM |
| Business Meeting | | 1:29 PM | 1:44 PM |
| <i>Transition</i> | | 1:44 PM | 1:46 PM |
| AMD - Non-neovascular Symposium 1. <i>Beyond Atrophy: Restoring Vision and Redefining Care in Geographic Atrophy</i> | | 1:46 PM | 2:10 PM |
| Vision Improvement with Sonporetigene Isteparvovec Optogenetic Therapy in Macular Degeneration: First Direct-to-Phase 2 Randomized, Controlled Trial | Jordi Mones, MD PhD | 1:46 PM | 1:49 PM |
| From Optical Modelling to First-in-Human Add-On Implantation of the SING IMT™: Translational Feasibility of Dual-Lens Intraocular Systems for Late-Stage AMD | Stanislao Rizzo, MD | 1:49 PM | 1:52 PM |
| Liquid Biopsy Proteomics: Deciphering the Molecular Mechanisms Behind Increased Neovascular AMD Risk After Anti-complement Therapy in Geographic Atrophy | Tsai-Chu Yeh, MD, MTM | 1:52 PM | 1:55 PM |
| Artificial Intelligence in GA: Learnings from the Pegcetacoplan Clinical Program | Paul Hahn, MD, PhD, FASRS | 1:55 PM | 1:58 PM |
| Discussion | | 1:58 PM | 2:10 PM |
| <i>Transition</i> | | 2:10 PM | 2:12 PM |
| Diabetic Retinopathy Panel 1. <i>Advancing Durability in Diabetic Retinopathy: New Therapies and Long-Term Data</i> | | 2:12 PM | 2:42 PM |
| Long-Term Effectiveness and Safety of Faricimab in Eyes With DME: 2-Year Results From the UK FARWIDE Study | Sobha Sivaprasad, FRCOphth | | |

| | | | |
|---|---|----------------|----------------|
| Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First-time, Primary Endpoint Results from the Phase 3 GLOW2 Trial | Charles Wykoff, MD, PhD, FASRS | | |
| Pagoda Trial Results Through Year 4: Port Delivery Platform With Ranibizumab for the Treatment of Diabetic Macular Edema | Luke Lindsell, OD, MD | | |
| Results of a Randomized, Proof-of-Concept Clinical Trial Comparing OLN324 with Faricimab in Patients with Diabetic Macular Edema | Veeral Sheth, MD, MBA, FASRS, FACS | | |
| Intravitreal Tarcocimab Tedromer for Diabetic Retinopathy: First- time Cross-trial Evaluation of the GLOW and GLOW2 Phase 3 Trials | David Brown, MD | | |
| Discussion | | | |
| Break | | 2:42 PM | 3:22 PM |
| Real-World Symposium 2. Managing Macular Edema in the Real World: What the Data Shows | | 3:22 PM | 3:46 PM |
| Two-Year Real-World Outcomes of Faricimab for Diabetic Macular Edema: Updated Results from the US FARETINA-DME Expanded 2 year cohort in the IRIS® Registry | Murtaza Adam, MD | 3:22 PM | 3:25 PM |
| Real-World Use of Aflibercept 8 mg in Eyes with Diabetic Macular Edema (DME): Analysis of the IRIS® Registry (ILLUMIN-8 6-mo) | Michael Klufas, MD | 3:25 PM | 3:28 PM |
| Durability and safety of suprachoroidal triamcinolone acetonide in eyes with chronic cystoid macular edema in real-world clinical practice | Sunir Garg, MD, FACS, FASRS | 3:28 PM | 3:31 PM |
| Real-World Clinical Outcomes in Patients With Retinal Vein Occlusion With Macular Edema Treated With Faricimab in the Academy IRIS® Registry | Rishi Singh, MD | 3:31 PM | 3:34 PM |
| Discussion | | 3:34 PM | 3:46 PM |
| <i>Transition</i> | | 3:46 PM | 3:48 PM |
| Macular Holes & Macular Pucker Panel 1. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes | | 3:48 PM | 4:13 PM |
| Impact of Phacoemulsification on Vitreomacular Traction Release and Complications | Ananth Sastry, MD | | |

| | | | |
|---|-------------------------------------|----------------|----------------|
| Beyond the Inverted Flap: Clinical utility of a non-inverted ILM free flap and SPOT technique for primary and refractory Macular Holes | Peiquan Zhao, MD | | |
| Predictors of Anatomic and Functional Success with Amniotic Membrane Grafting for Complex Macular Holes | Scott Walter, MD, MSc, FASRS | | |
| Distal ILM Flap for Extra-large, XX-large, and Giant Macular Holes | Homayoun Tabandeh, MD, FASRS | | |
| Discussion | | | |
| <i>Transition</i> | | 4:13 PM | 4:15 PM |
| Technology: Updates in Artificial Intelligence (AI), Augmented Reality, and Robotics. AI in Retina: From Prediction to Clinical and Surgical Decision-Making | | 4:15 PM | 4:39 PM |
| Prospective Evaluation of AI-Assisted Screening for Clinical Trials in a Real World Setting | Louis Cai, MD | 4:15 PM | 4:18 PM |
| Predicting Anti-VEGF Treatment Response in Diabetic Macular Edema Using Automated OCT Biomarkers | Peter Clark, MD | 4:18 PM | 4:21 PM |
| OCT-F: An AI-Enabled Tool to Determine Retinal Function from OCT | Srinivas Sadda, MD | 4:21 PM | 4:24 PM |
| bu | Michael Singer, MD | 4:24 PM | 4:27 PM |
| Discussion | | 4:27 PM | 4:39 PM |
| <i>Transition</i> | | 4:39 PM | 4:41 PM |
| Macular Holes & Macular Pucker Symposium. Beyond the ILM Flap: Advanced Techniques for Complex Macular Holes | | 4:41 PM | 5:05 PM |
| Redefining Anatomic Success After Vitrectomy for Lamellar Macular Hole (LMH): Clinical Impact of Persistent or Recurrent LMH and Progression to Full-Thickness Macular Hole | Masaki Fukushima, MD | 4:41 PM | 4:44 PM |
| Spontaneous Progression from Lamellar Macular Hole to Full-Thickness Macular Hole: Timing, Characteristics, and Surgical Outcomes | Kotaro Tsuboi, MD | 4:44 PM | 4:47 PM |
| Postoperative stages of macular hole recovery through transfluid optical coherence tomography: a comparison between minimal gas vitrectomy and fluid-gas exchange | Yodpong Chantarasorn, MD | 4:47 PM | 4:50 PM |

| | | | |
|--|--|----------------|----------------|
| Early Epiretinal Membrane Surgery Is Associated With Improved Visual Outcomes After Macula-On Retinal Detachment: A Large Database Study | Paul de Bustros, MD, MS | 4:50 PM | 4:53 PM |
| Discussion | | 4:53 PM | 5:05 PM |
| Transition | | 5:05 PM | 5:10 PM |
| Scientific Poster Q&A and Exhibit Hall Reception | | 5:10 PM | 6:10 PM |
| Friday, July 17 | | | |
| Experience Center (Fellows & Residents) | | 6:30 AM | 7:30 AM |
| Continental Breakfast | | 7:15 AM | 8:15 AM |
| AMD - Neovascular Symposium 2. <i>Innovations in nAMD: New Targets, New Therapies, Early Results</i> | | 8:00 AM | 8:19 AM |
| First-in-Human Evaluation of TH103, a Novel Dual-Targeting VEGF/HSPG Biologic: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD | Joel Pearlman, MD, PhD | 8:00 AM | 8:03 AM |
| Efficacy and Safety of a Novel Topical Peptide (CG-P5) for the Treatment of Neovascular Age-Related Macular Degeneration: Phase 1 Results | David Almeida, MD, MBA, PhD, DABO, FRCSC, FASRS | 8:03 AM | 8:06 AM |
| Randomized, Controlled, Double-Masked Study to Evaluate the Antimicrobial Efficacy of IRX-101: STERILE Trial Results | STEPHEN SMITH, MD | 8:06 AM | 8:09 AM |
| Discussion | | 8:09 AM | 8:19 AM |
| Transition | | 8:19 AM | 8:21 AM |
| AMD - Non-neovascular Symposium 2. <i>Emerging Therapies in Geographic Atrophy: Gene Therapy, RNA, and Novel Pathways</i> | | 8:21 AM | 8:45 AM |
| Subretinal Novel Modifier Gene Therapy (OCU410) for Geographic Atrophy: First-Time 1 year Results from the Phase 2 ArMaDa Trial. | Arshad Khanani, MD, MA, FASRS | 8:21 AM | 8:24 AM |
| Phase 1/2 Evaluation of OCU410 Novel Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Quantitative FAF and SD-OCT Lesion Analysis and Safety Outcomes | Jay Chhablani | 8:24 AM | 8:27 AM |
| Phase 1 results of APL-3007: A novel systemic C3 siRNA for geographic atrophy secondary to AMD | Mathew MacCumber, MD, PhD | 8:27 AM | 8:30 AM |

| | | | |
|--|--------------------------|----------------|----------------|
| A Phase 2 Clinical Trial of the Inflammasome Inhibitor K8 in Bilateral Geographic Atrophy (GA) | Jayakrishna Ambati, MD | 8:30 AM | 8:33 AM |
| Discussion | | 8:33 AM | 8:45 AM |
| <i>Transition</i> | | 8:45 AM | 8:47 AM |
| Closing the Gap: Translating Emerging Therapies into Real-World Outcomes in GA | | 8:47 AM | 9:11 AM |
| Outcomes in Geographic Atrophy: Real-World Evidence from EHR Data and AI-Based Imaging in Patients Treated with Pegcetacoplan | Nimesh Patel, MD, FASRS | 8:47 AM | 8:50 AM |
| Earlier treatment yields better outcomes: 5 years of pegcetacoplan treatment for geographic atrophy secondary to AMD | Esther Kim, MD | 8:50 AM | 8:53 AM |
| Real-World Utilization, Retention, Safety, and Outcomes of Pegcetacoplan Therapy for Geographic Atrophy in Patients with Follow-up of Two Years | Alexander Miller, MD | 8:53 AM | 8:56 AM |
| Assessment of Geographic Atrophy Progression Following Pegcetacoplan in the Real-world With and Without Neovascular Age-related Macular Degeneration | Hasenin Al-khersan, MD | 8:56 AM | 8:59 AM |
| Discussion | | 8:59 AM | 9:11 AM |
| <i>Transition</i> | | 9:11 AM | 9:13 AM |
| Inflammatory and Infectious Diseases Symposium. Uveitis and Ocular Infection: Evolving Diagnosis and Treatment Strategies | | 9:13 AM | 9:54 AM |
| Safety of Anti-VEGF Injections in Patients with Uveitis | Mitchell Allphin, MD | 9:13 AM | 9:16 AM |
| Long term visual, anatomical and treatment outcomes in eyes | Sruthi Arepalli, MD | 9:16 AM | 9:19 AM |
| Ocular Syphilis and Regional Variation in Lumbar Puncture | Mark Breazzano, MD, FACS | 9:19 AM | 9:22 AM |
| Discussion | | 9:22 AM | 9:32 AM |
| Disease-Modifying Strategies in Autoimmune Retinopathy | Majda Hadziahmetovic, MD | 9:32 AM | 9:35 AM |
| Long-Term Outcomes of Pediatric Vogt–Koyanagi–Harada Disease | Sulaiman Al Sulaiman, MD | 9:35 AM | 9:38 AM |
| Postoperative Sarocladium kiliense endophthalmitis | Makoto Inoue, MD, FASRS | 9:38 AM | 9:41 AM |
| Multimodal Suprachoroidal Space Imaging Reveals Opening | Glenn Yiu, MD, PhD | 9:41 AM | 9:44 AM |
| Discussion | | 9:44 AM | 9:54 AM |
| <i>Transition</i> | | 9:54 AM | 9:56 AM |

| | | | |
|---|---|-----------------|-----------------|
| Trauma & PVR Symposium. <i>Decision-Making, Surgical Strategies, and Case-Based Insights</i> | | 9:56 AM | 10:05 AM |
| Objective Ocular Trauma Score (oOTS): A Visual Acuity-Independent Model With Discrimination Comparable to OTS | Shulamit Schwartz, MD | 9:56 AM | 9:59 AM |
| tPA-Assistant Trauma Surgery | Adiel Barak, MD | 9:59 AM | 10:02 AM |
| Outcomes of Complex PVR Retinal Detachment Repair with and without Intravitreal Methotrexate at a Single Tertiary Care Center | John Miller, MD | 10:02 AM | 10:05 AM |
| Break | | 10:05 AM | 10:45 AM |
| Hereditary Retinal Disease & Genetics Symposium. <i>Emerging Therapeutic and Diagnostic Advances in Inherited Retinal Diseases</i> | | 10:45 AM | 11:06 AM |
| Intravitreal RNA Therapy for PRPF31-Associated Retinitis Pigmentosa: Results from a Phase 1b Multiple Ascending Dose Study of VP-001 | Robert Bhisitkul, MD, PhD | 10:45 AM | 10:48 AM |
| Subretinal laru-zova Gene Therapy for XLRP: Preliminary Safety, Efficacy and Surgical Technique in the Phase 2 Multicenter DAWN Trial | Robert Sisk, MD, FACS, FASRS | 10:48 AM | 10:51 AM |
| Enhancing Molecular Diagnostic Accuracy in Inherited Retinal Dystrophies Through a Personalized Re-Evaluation Strategy | João Pedro Marques, MD, MSc, PhD, FEBOphth | 10:51 AM | 10:54 AM |
| Discussion | | 10:54 AM | 11:06 AM |
| <i>Transition</i> | | 11:06 AM | 11:08 AM |
| Diabetic Retinopathy Symposium. <i>Innovations in Diabetic Retinopathy: New Therapies, Delivery Systems, and Disease Biology</i> | | 11:08 AM | 11:38 AM |
| Oral Tonabersat Connexin-43 Modulator for Diabetic Macular Edema with Good Vision (DRCR Protocol AN) | Andrew Barkmeier, MD | 11:08 AM | 11:11 AM |
| Sustained-release PER-001 Intravitreal Implant: Structural and Visual Function Improvements in Patients with Diabetic Retinopathy | Saradha Chexal, MD | 11:11 AM | 11:14 AM |
| Suprachoroidal Delivery of Investigational Gene Therapy Surabgene Lomparvovec (Sura-vec, ABBV-RGX-314): Results in NPDR at 2.5 Years | David Boyer, MD | 11:14 AM | 11:17 AM |

| | | | |
|---|--|-----------------|-----------------|
| Adrenaline vs Tranexamic Acid for Intraoperative Hemostasis in PDR Vitrectomy: A Randomized Trial | SHISHIR VERGHESE, MS, FVRS, FAICO (Retina) | 11:17 AM | 11:20 AM |
| Fellows Forum Award Winner: Multiomic analysis of human diabetic retinal disease reveals severity and region-specific impairment of the retinal neurovascular unit | Rachana Haliyur, MD, PhD | 11:20 AM | 11:23 AM |
| Discussion | | 11:23 AM | 11:38 AM |
| <i>Transition</i> | | 11:38 AM | 11:40 AM |
| Retinal Vascular Disease Symposium. <i>Retinal Vascular Occlusions: Treatment Strategies, Outcomes, and Emerging Approaches</i> | | 11:40 AM | 12:18 PM |
| Tiespectus (MK-8748) for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Phase 1/2a Rioja Clinical Study | Baruch Kuppermann, MD, PhD, FASRS | 11:40 AM | 11:43 AM |
| Retinal Vein Occlusion with Good Baseline Visual Acuity: Immediate Treatment vs. Initial Observation | Ajay Kuriyan, MD, MS | 11:43 AM | 11:46 AM |
| Impact of Baseline Central Retinal Thickness on Visual and Anatomic Outcomes in Macular Edema Following RVO: A QUASAR Post hoc analysis through Wk 36 | Ehsan Rahimy, MD | 11:46 AM | 11:49 AM |
| Discussion | | 11:49 AM | 11:59 AM |
| Outcomes after low-IOP vitrectomy combined with arteriovenous sheathotomy, ILM peeling with a brief induced IOP fluctuation in Central Retinal Artery Occlusion | Subhendu Boral, MBBS, MD(AIIMS), DNB, FASRS (USA) | 11:59 AM | 12:02 PM |
| Clinical Outcomes of Switching Back to Intravitreal Bevacizumab Therapy | Mary Gao, DO | 12:02 PM | 12:05 PM |
| Detecting retrobulbar emboli with orbital ultrasonography to predict neovascular glaucoma in central retinal artery occlusion | Erik Massenzio, MD | 12:05 PM | 12:08 PM |
| Discussion | | 12:08 PM | 12:18 PM |
| General Lunch + Fellowship Directors Section Lunch | | 12:18 PM | 1:33 PM |
| Socioeconomics/Practice Management Panel. <i>Health Systems and Equity in Retina Care</i> | | 1:33 PM | 2:03 PM |
| Impact of Social Deprivation and Vulnerability on Patients With DME: Results From ELEVATUM and YOSEMITE/RHINE | Mohsin Ali, MD | | |
| Baseline Biomarker Levels in Underrepresented Patients With DME: A Post Hoc Exploratory Analysis of ELEVATUM | Adrienne Scott, MD, FASRS | | |

| | | | |
|--|-----------------------------------|----------------|----------------|
| Real-World Impact of Step Therapy Requirements on Access to Faricimab and Treatment Burden | Sabin Dang, MD | | |
| Impact of Loss of Good Days Copay Assistance Program on Clinical and Anatomical Outcomes of Retinal Disease | Danny Mammo, MD | | |
| Impact of Good Days Underfunding on Treatment Patterns and Outcomes in Patients with Neovascular Age-Related Macular Degeneration | Abdullah Abou-Samra, MD | | |
| Discussion | | | |
| <i>Transition</i> | | 2:03 PM | 2:05 PM |
| Policy Panel | | 2:05 PM | 2:30 PM |
| <i>Transition</i> | | 2:30 PM | 2:32 PM |
| Socioeconomics/Practice Management Symposium. Health Disparities in Retina Care: Policy, Geography, and Population Outcomes | | 2:32 PM | 3:10 PM |
| Access to Intravitreal Anti-VEGF Drugs in Persons with Medicare Advantage Compared with Medicare Fee for Service | Ravi Parikh, MD MPH | 2:32 PM | 2:35 PM |
| Comparison of Medicaid vs Medicare Reimbursements Rates for Vitreoretinal Surgeries in the United States | Ella Leung, MD | 2:35 PM | 2:38 PM |
| Diabetic Retinopathy Outcomes Among Unhoused Individuals: A Big Data Analysis | Judy Kim, MD, FARVO, FASRS | 2:38 PM | 2:41 PM |
| Discussion | | 2:41 PM | 2:51 PM |
| Impact of Geographic and Socioeconomic Factors on Endophthalmitis Presentation and Outcomes | Bivek Wagle, MD | 2:51 PM | 2:54 PM |
| Access to Pediatric Retina Care by Geographic Distribution and US Population Demographic Characteristics in 2025 | Hong-Uyen Hua, MD | 2:54 PM | 2:57 PM |
| The effects of Social and Demographic Factors on Severity of Inherited Retinal Diseases at the Time of Genetic Testing | Milam Brantley, MD, PhD | 2:57 PM | 3:00 PM |
| Discussion | | 3:00 PM | 3:10 PM |
| <i>Transition</i> | | 3:10 PM | 3:12 PM |
| Panel Discussion: Impact of Vitrectomy on Light Adjustable Lenses Before Final Laser Lock-in in Post-Cataract Surgery Patients | Osama Sabbagh, MD | 3:12 PM | 3:27 PM |
| Break | | 3:27 PM | 4:07 PM |

| Pediatric Retina - The Michael Trese Symposium in Pediatric Retina | | 4:07 PM | 4:50 PM |
|---|---|----------------|----------------|
| ICROP3 Zone I Definition Varies with Post Menstrual Age and is Not Consistent with Type 1 ETROP Treatment Zone I Definition | Darius Moshfeghi, MD, FASRS | 4:07 PM | 4:10 PM |
| Tele-screening is associated with reduced treatment rates in a large cohort of infants at risk for retinopathy of prematurity. | Eugenia Greig, MD | 4:10 PM | 4:13 PM |
| Retinopathy of Prematurity in Infants Born at 22 Weeks of Gestational Age | Sahal Saleh, MD | 4:13 PM | 4:16 PM |
| Discussion | | 4:16 PM | 4:26 PM |
| Atypical regression patterns of Retinopathy of Prematurity, post combined therapy with intravitreal Anti-VEGF and laser photocoagulation. | Bibhuti Kashyap, MD, FACS, DNB, FRCSEd, FRCS (GLASGOW), FICO | 4:26 PM | 4:29 PM |
| Outcomes of a combined surgical approach for stage 5 ROP: A prospective interventional case series | Sameera Nayak, MBBS, MS, FRCS | 4:29 PM | 4:32 PM |
| Choroidal Vascularity Index and Choroidal Area in Stage 3+ ROP Eyes Treated With Anti-VEGF With or Without Laser | Swati Agarwal-Sinha, MD, FASRS | 4:32 PM | 4:35 PM |
| Comparative Axial Elongation Rates in High Myopia With and Without Retinopathy of Prematurity | Melissa Yuan, MD | 4:35 PM | 4:38 PM |
| Discussion | | 4:38 PM | 4:50 PM |
| <i>Transition</i> | | 4:50 PM | 4:52 PM |
| MacTel Panel. Macular Telangiectasia Type 2: Imaging, Emerging Therapies, and Clinical Outcomes | | 4:52 PM | 5:22 PM |
| Ellipsoid Zone Area Loss Is an Independent Predictor of Reduced Fixation Stability in Macular Telangiectasia Type 2 | Eleonora Lad, MD, PhD | | |
| Longitudinal Multimodal Imaging and Clinical Outcomes in Individuals Who Received Revakinagene Taroretcel-Iwey Encapsulated Cell Therapy for MacTel | Lydia Sauer, MD | | |
| Reading Speed Outcomes in Macular Telangiectasia Type 2: Sham-Control Data From the Phase 3 Revakinagene Taroretcel-Iwey (NT-501) Trials | Dean Elliott, MD | | |
| Surgical-Related Adverse Events With Revakinagene Taroretcel-Iwey in Macular Telangiectasia Type 2: A Root Cause Analysis | W. Clark, MD, FASRS | | |

| | | | |
|---|---------------------------------------|----------------|----------------|
| Misdiagnosis of Macular Telangiectasia Type 2 in the Era of Neuroprotective Therapy Discussion | Robin Vora, MD | | |
| Transition | | 5:22 PM | 5:30 PM |
| WinR Case Conference | | 5:30 PM | 7:15 PM |
| FIT & Resident Reception | | 6:00 PM | 8:00 PM |
| Saturday, July 18 | | | |
| Empowerment & Opportunity Mentoring Breakfast | | 6:00 AM | 8:00 AM |
| Experience Center (Fellows & Residents) | | 6:30 AM | 7:30 AM |
| Continental Breakfast | | 7:15 AM | 8:15 AM |
| Retinal Detachment Panel. <i>Retinal Detachment: PVR Prevention, Surgical Outcomes, and Risk Factors</i> | | | |
| | | 8:00 AM | 8:20 AM |
| Statin Use and Association with Proliferative Vitreoretinopathy and Reoperation Risk Following Retinal Detachment Surgery | Christina Weng, MD, MBA, FASRS | | |
| Trends in Centralization of Urgent Versus Elective Vitreoretinal Surgery in the Medicare Fee-For-Service Population: 2017-2023 | Stephanie Engelhard, MD | | |
| Interim Report #2 of the FIXER - Methotrexate Trial (Prevention of Proliferative Vitreoretinopathy with Intravitreal Methotrexate in Primary Retinal Detachment Repair) | Christopher Riemann, MD | | |
| Discussion | | | |
| <i>Transition</i> | | 8:20 AM | 8:22 AM |
| Retinal Detachment Symposium 1. <i>Retinal Detachment: Risk Stratification, Prophylaxis, and Imaging Insights</i> | | | |
| | | 8:22 AM | 8:46 AM |
| Retinopexy prophylaxis of lattice degeneration in fellow eyes after rhegmatogenous detachment: results from a large national database | Ahmed Shakarchi, MD, MPH | | |
| | | 8:22 AM | 8:25 AM |

| | | | |
|--|--|-----------------|-----------------|
| Retinopexy Prophylaxis for Lattice Degeneration Without Retinal Breaks: A Large Retrospective Cohort Study | Ahmed Sallam, MD PhD FRCOphth | 8:25 AM | 8:28 AM |
| Outer Retinal Corrugations Indicate Retinal Break Status in Rhegmatogenous Retinal Detachment | Jeffrey Mah, MD | 8:28 AM | 8:31 AM |
| Outer Retinal Corrugation Biomechanics Predict Outer Retinal Folds and Visual Acuity in Rhegmatogenous Retinal Detachment | Isabela Martins Melo, MD | 8:31 AM | 8:34 AM |
| Discussion | | 8:34 AM | 8:46 AM |
| <i>Transition</i> | | 8:46 AM | 8:48 AM |
| Hereditary Retinal Disease & Genetics Panel. <i>Stargardt Disease: Emerging Therapies, Biomarkers, and Clinical Trial Design</i> | | 8:48 AM | 9:13 AM |
| Results of the Phase 3 DRAGON Trial of Tinlarebant (LBS-008) for Stargardt Disease (STGD1) | Paul Bernstein, MD, PhD | | |
| Oral Gildeuretinol for Slowing Stargardt Disease Progression: Safety and Efficacy Data from the Phase 2 TEASE Study and Follow-up Phase 3 Study Design | Christine Kay, MD | | |
| Relationship of Three Atrophy Growth Rate Metrics with Lesion Shape Factors in Stargardt Disease: Implications for Clinical Trial Design | Liangbo Shen, MD | | |
| Automated Quantification of Decreased FAF in Stargardt Disease Using Starguage: Validation Against Manual Grading Standards | Jia-Horung Hung, MD, PhD | | |
| Discussion | | | |
| <i>Transition</i> | | 9:13 AM | 9:15 AM |
| Best of JVRD and Journal Updates | Moderator: Timothy Murray, MD, MBA, FASRS | 9:15 AM | 9:30 AM |
| <i>Transition</i> | | 9:30 AM | 9:32 AM |
| Break | | 9:32 AM | 10:12 AM |
| Pharmacology Symposium. <i>Balancing Risk and Benefit: Pharmacologic Safety in Retina Care</i> | | 10:12 AM | 10:36 AM |
| Association of Peri-Event Anti-VEGF with Mortality and Sequelae Following Stroke or Myocardial Infarction | Darius Bordbar, MD | 10:12 AM | 10:15 AM |

| | | | |
|---|---|-----------------|-----------------|
| Safety of Continuing Anti-VEGF Therapy Around the Time of Nonophthalmic Incisional Surgery: A Multisite Matched Cohort Study | Odette Houghton, MD | 10:15 AM | 10:18 AM |
| 'Drop less Vitrectomy' with 'Suprachoroidal Trimoxi' for epiretinal membranes: A Comparative Analysis of Safety and Efficacy with standard of care topi | K. Chalam, MD, PhD, MBA, FRCS(C), FASRS | 10:18 AM | 10:21 AM |
| A Pilot Study Evaluating Safety and Patient Comfort of a Compounded Povidone-Iodine and Proparacaine Combination | Ivan Suñer, MD, MBA | 10:21 AM | 10:24 AM |
| Discussion | | 10:24 AM | 10:36 AM |
| <i>Transition</i> | | 10:36 AM | 10:38 AM |
| AMD - Non-neovascular Symposium 3. Geographic Atrophy: Functional Outcomes, Treatment Response, and Predictive Biomarkers | | 10:38 AM | 10:57 AM |
| Structure–Function Link of the Ellipsoid Zone and Low Luminance Deficit in Geographic Atrophy with Monthly and Every-Other-Month Avacincaptad Pegol | Rachel Downes, MD | 10:38 AM | 10:41 AM |
| Pegcetacoplan versus Avacincaptad pegol: Efficacy of Treatment in the Same Eye | Josh Wallsh | 10:41 AM | 10:44 AM |
| Baseline Characteristics Associated With Loss of BCVA \geq 15 ETDRS Letters in Participants With Geographic Atrophy in the Phase 2 ARCHER Study | Margaret Chang, MD, MS | 10:44 AM | 10:47 AM |
| Discussion | | 10:47 AM | 10:57 AM |
| <i>Transition</i> | | 10:57 AM | 10:59 AM |
| Real-World Retina: Outcomes, Complications, and Risk Stratification | | 10:59 AM | 11:30 AM |
| Incidence, prevalence and risk factors for pathologic myopia and associated complications: a multi-center database study | Michael Flitsos, MD | 10:59 AM | 11:02 AM |
| Incidence and risk factors of retinal tear and detachment after YAG capsulotomy: an IRIS [®] Registry (Intelligent Research in Sight) analysis | Jordan Deaner, MD | 11:02 AM | 11:05 AM |
| Ten-Year Real-World Outcomes of Intravitreal Antibiotics Alone, Deferred Vitrectomy, and Immediate Vitrectomy for Acute Post-Cataract Endophthalmitis | Aditya Kelkar, MS, FRCS, FASRS, FRCOphth | 11:05 AM | 11:08 AM |

| | | | |
|--|---|-----------------|-----------------|
| Discussion | | 11:08 AM | 11:18 AM |
| Endophthalmitis Following Pars Plana Vitrectomy: An IRIS® Registry Study | Matthew Starr, MD, FASRS | 11:18 AM | 11:21 AM |
| Proliferative Vitreoretinopathy in Contemporary Retinal Detachment Surgery: Socioeconomic, Surgical, and Ocular Determinants in the IRIS® Registry | Leo Kim, MD, PhD | 11:21 AM | 11:24 AM |
| Discussion | | 11:24 AM | 11:30 AM |
| <i>Transition</i> | | 11:30 AM | 11:32 AM |
| Macular Holes & Macular Pucker Panel 2. Macular Surgery Complications: Outcomes After Vitrectomy for Hole and Pucker | | 11:32 AM | 11:57 AM |
| Persistent cystoid macular edema after vitrectomy for epiretinal membrane removal | Libby Wei, MD | | |
| Epiretinal Membrane Risk After Prophylactic Laser Photocoagulation for Lattice Degeneration | Marta Stevanovic, MD, MSc | | |
| Increased Risk of Retinal Detachment in Combined Phacovitrectomy versus Sequential Surgery for Macular | Charles Zhang, MD | | |
| Progression of Macular Atrophy after Vitrectomy for Myopic Traction Maculopathy: Incidence, Risk Factors, and Outcomes | Taku Wakabayashi, MD, PhD | | |
| Discussion | | | |
| General Lunch + WinR Lunch | | 11:57 AM | 1:12 PM |
| Retinaws | Moderator: Kourous Rezaei, MD | 1:12 PM | 2:12 PM |
| | Panelists: Audina Berrocal, MD, FASRS; Maria Berrocal, MD; Geoffrey G. Emerson, MD, PhD, FASRS; Gustavo Hüning, MD, MBA, FASRS; Makoto Inoue, MD, FASRS; Kazuaki Kadonosono, MD; Stanislao Rizzo, MD; Gaurav Shah, MD; Christina Weng, MD, MBA, FASRS; Charles Wykoff, MD, PhD, FASRS | | |
| <i>Transition</i> | | 2:12 PM | 2:14 PM |
| Ocular Oncology Symposium. Uveal Melanoma: From Biopsy to Biomarkers to Clinical Decision-Making | | 2:14 PM | 2:44 PM |

| | | | |
|--|---------------------------------------|----------------|----------------|
| Viscous Fluid Control Assisted Fine-Needle Aspiration Biopsy for Uveal Melanoma: Surgical Technique | Gordon Crabtree, MD | 2:14 PM | 2:17 PM |
| Gene Expression Profiling for Uveal Melanoma: The first decade and beyond defines best care for our patients | Timothy Murray, MD, MBA, FASRS | 2:17 PM | 2:20 PM |
| Limits of Mutation Profiling as a Predictor of 15-GEP/PRAME Risk in Uveal Melanoma | David Reichstein, MD | 2:20 PM | 2:23 PM |
| Clinicopathologic characteristics, gene expression, and metastatic risk of uveal melanomas with no uveal melanoma-associated mutations (no UMAMs) | Amy Scheffler, MD FACS FASRS | 2:23 PM | 2:26 PM |
| Prophylactic bevacizumab after Plaque Brachytherapy in high-risk posterior uveal melanoma: Impact on development of radiation retinopathy | Prithvi Mruthyunjaya, MD, MHS | 2:26 PM | 2:29 PM |
| Discussion | | 2:29 PM | 2:44 PM |
| Break | | 2:44 PM | 3:24 PM |
| Best of Business of Retina | Moderator: Thomas Stone, MD | 3:24 PM | 3:39 PM |
| <i>Transition</i> | | 3:39 PM | 3:41 PM |
| Creative Awards | | 3:41 PM | 4:06 PM |
| <i>Transition</i> | | 4:06 PM | 4:08 PM |
| Diabetic Retinopathy Panel 2. <i>Diabetic Retinopathy: Outcomes and Predictors</i> | | 4:08 PM | 4:33 PM |
| Impact of Baseline Subretinal Fluid on Treatment Outcomes in DME: Analysis of the Phase 3 YOSEMITE and RHINE Trials | Rolake Alabi, MD PhD | | |
| Baseline Macular Vascular Status Determines Perfusion and Visual Recovery After Panretinal Photocoagulation in Severe Diabetic Retinopathy Without Macular Edema | Eoi Jong Seo, MD, PhD | | |
| Assessment of Intraretinal Cyst Turbidity on Optical Coherence Tomography: Clinical Implications in DME From YOSEMITE/RHINE | Andreas Pollreisz, MD | | |
| The Association Between Diabetic Retinopathy Severity and Dementia Risk | Manju Subramanian, MD | | |
| Discussion | | | |
| <i>Transition</i> | | 4:33 PM | 4:35 PM |

| Retinal Detachment Symposium 2. <i>Beyond Routine RD: Complex Cases, AI Prediction, and Surgical Decision-Making</i> | | 4:35 PM | 4:59 PM |
|--|---|----------------|----------------|
| Predicting the Location of Retinal Tears in Eyes with Rhegmatogenous Retinal Detachment Using Artificial Intelligence | John Thompson, MD | 4:35 PM | 4:38 PM |
| Clinical features of retinal detachment (RD) following prophylactic retinopexy in children with Stickler syndrome: implications for optimal treatment and management | Franco Recchia, MD | 4:38 PM | 4:41 PM |
| Colobomatous Retinal Detachments: A Single Center Retrospective Analysis | Amer Alsoudi, MD | 4:41 PM | 4:44 PM |
| Scleral Buckle Revision in the Vitrectomy Era | Irmak Karaca, MD, FEBO, FICO, MRCSEd | 4:44 PM | 4:47 PM |
| Discussion | | 4:47 PM | 4:59 PM |
| Closing Reception: Marche Bonsecours | | 7:00 PM | |